Trending News

Blog Post


Ark Make investments analyst breaks down Adaptive Biotechnologies and Invitae 

Chad Robins, CEO of Adaptive Biotechnologies.

Anjali Sundaram | CNBC

Ark Make investments analyst Simon Barnett on Monday defined the agency’s method to what it calls the genomic revolution, breaking down two of its favourite holdings: Adaptive Biotechnologies and Invitae.

In an interview on CNBC’s “Closing Bell,” Barnett mentioned the Cathie Wooden-led Ark Make investments sees main potential for traders within the department of molecular biology referred to as genomics, calling it “one of the crucial transformative funding alternatives of the century.”

Ark’s household of funds consists of the Genomic Revolution ETF (ARKG), which seeks to supply traders publicity to areas resembling DNA sequencing expertise and molecular diagnostics.

ARKG is down about 7% yr up to now.

Nonetheless, up to now 12 months, the ETF has risen roughly 160%. The agency’s flagship fund is the Ark Innovation ETF (ARKK), which has fallen about 1.6% to this point in 2021. ARKK is also up practically 160% up to now 12 months.

Supply hyperlink

Related posts

Leave a Reply

Required fields are marked *